会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS
    • 作为JAK抑制剂的吡唑并[1,5-A]吡嗪-4-基衍生物
    • WO2017144995A1
    • 2017-08-31
    • PCT/IB2017/050748
    • 2017-02-10
    • PFIZER INC.
    • BROWN, Matthew FrankDERMENCI, AlpayFENSOME, AndrewGERSTENBERGER, Brian StephenHAYWARD, Matthew MerrillOWEN, Dafydd RhysWRIGHT, Stephen WayneXING, Li HuangYANG, Xiaojing
    • C07D487/04A61K31/4985A61P37/02A61P29/00A61P25/28
    • C07D487/04
    • A compound compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A' and A" are independently O, C=O, C-R' or N-R", where R' and R" may independently be H, amino, -NR 7 COR 6 , COR 6 , -CONR 7 R 8 , C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl), and R" may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A' and A" is O or C=0; R 0 and R are independently H, Br, CI, F, or C 1 -C 6 alkyl; R 1 is H, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl); R 2 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy(C 1 -C 6 alkyl), phenyl(C 1 -C 6 alkyl), formyl, heteroaryl, heterocyclic, -COR 6 , -OCOR 6 , -COOR 6 , -NR 7 COR 6 , -CONR 7 R 8 , and -(CH 2 ) n -W, where W is cyano, hydroxy, C 3 -C 8 cycloalkyl, -SO 2 NR 7 R 8 , and -SO 2 -R 9 , where R 9 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C 1 -C 6 alkyl; X is C-R 3 or N, where R 3 may be H or C 1 -C 6 alkyl; R 4 and R 5 are independently H, amino, C 1 -C 6 alkyl, or hydroxy(C 1 -C 6 alkyl); R 6 , R 7 and R 8 are each independently H, C 1 -C 6 alkyl, C 1 -C 4 alkoxy(C 1 -C 6 alkyl), or C 3 -C 8 cycloalkyl, said C 1 - C 6 alkyl is optionally substituted by halo, CN or hydroxy; or, R 7 and R 8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C 1 -C 6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
    • 具有结构(I)的化合物或其可药用盐,或所述化合物或其可药用盐的可药用溶剂化物,其中A,A'和A“ 独立地为O,C = O,C-R'或N-R“,其中R'和R” 可以独立地为H,氨基,-NR 7 COR 6,COR 6,-CONR 7 R 9, C 1 -C 6烷基或羟基(C 1 -C 6)烷基或C 1 -C 6烷基, 烷基),并且R“ 可以存在或不存在,并且存在于价数规则允许的地方,并且A,A'和A“中不多于一个的地方存在。 是O或C = 0; R 0和R独立地为H,Br,Cl,F或C 1 -C 6烷基; R 1是H,C 1 -C 6烷基或羟基(C 1 -C 4)烷基, C 1-6烷基); R 2选自H,C 1 -C 6烷基,C 1 -C 4烷基,C 1 -C 4烷基, C 1-6烷氧基,羟基(C 1 -C 6烷基),苯基(C 1 -C 6烷基) C 1-6烷基),甲酰基,杂芳基,杂环基,-COR 6,-OCOR 6,-COOR 6,-NR 6 R 6, (COR 6),-CONR 7 R 8和 - (CH 2) 其中W为氰基,羟基,C 3 -C 8环烷基,-SO 2 NR 其中R 9,R 8,R 8,R 9,R 9,R 9,R 9, 是C 1 -C 6烷基,C 3 -C 8环烷基,杂芳基或杂环基; 其中所述烷基,环烷基,杂环或杂芳基中的每一个可以未被取代或被卤素,氰基,羟基或C 1 -C 6烷基取代; X是C-R 3或N,其中R 3可以是H或C 1 -C 6烷基; R 4和R 5独立地为H,氨基,C 1 -C 6烷基或羟基(C 1 - (C 1 -C 6烷基); R 6,R 7和R 8各自独立地为H,C 1 -C 6, C 1 -C 4烷氧基(C 1 -C 6烷基)或C(C 1 -C 6)烷基,C 1 -C 4烷氧基(C 1 -C 6烷基) 所述C 1 -C 6 - 烷基任选被卤素,CN或羟基取代 ; 或者R 7和R 8与其键合的原子一起形成5-或6-元环,所述环任选被卤素,羟基,CN或 C 1 -C 6烷基; C 1 -C 6烷基; 并且n为0,1,2或3.还提供了作为Janus激酶抑制剂和含有本发明化合物及其与其它治疗剂的组合的药物组合物的治疗方法。